Insider / BOSTON SCIENTIFIC CORP
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC at BOSTON SCIENTIFIC CORP
- Company
- BOSTON SCIENTIFIC CORP
- Ticker
- BSX
- First filing on record
- December 2, 2025
- Latest trade on record
- May 2, 2026
- SEC filings
- EDGAR ↗
Butcher Arthur C, EVP& Grp Pres, MedSurg & APAC at BOSTON SCIENTIFIC CORP, has disclosed 29 transactions in BSX since December 2, 2025: 0 purchases (0 open-market buys) and 6 sales, worth about $4.9M at the reported prices. The latest was filed May 4, 2026, 2 days after the trade; 11 filings were late against the 2-business-day Form 4 deadline.
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
In the last 12 months Butcher Arthur C made no purchases and 6 sales worth $4.0M, plus 23 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Butcher Arthur C has traded 1 stock on record; the largest by dollars is BSX.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
3 of 5 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 18 | 60,126 | $429K |
| F | Shares withheld for tax | 5 | 30,223 | $2.2M |
| A | Grant or award | 4 | 101,755 | — |
| I | Discretionary transaction | 1 | 6,851 | $519K |
| S | Open-market sale | 1 | 17,313 | $1.8M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 20 | 0 | 5 · $2.2M |
| 2025 | 9 | 0 | 1 · $1.8M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| BSX | Option / conversion M | May 2, 2026 | May 4, 2026 | 2d | 2,102 | — | — | derivative | Form 4 ↗ | |
| BSX | Sell F | May 2, 2026 | May 4, 2026 | 2d | 1,007 | $57 | $57K | Form 4 ↗ | ||
| BSX | Option / conversion M | May 2, 2026 | May 4, 2026 | 2d | 2,102 | — | — | Form 4 ↗ | ||
| BSX | Other I | February 19, 2026 | February 27, 2026 | 8d | 6,851 | $76 | $519K | lateindirect | Form 4 ↗ | |
| BSX | Option / conversion M | February 16, 2026 | February 18, 2026 | 2d | 2,546 | — | — | derivative | Form 4 ↗ | |
| BSX | Option / conversion M | February 14, 2026 | February 18, 2026 | 4d | 3,173 | — | — | derivative | Form 4 ↗ | |
| BSX | Option / conversion M | February 13, 2026 | February 18, 2026 | 5d | 2,237 | — | — | latederivative | Form 4 ↗ | |
| BSX | Sell F | February 16, 2026 | February 18, 2026 | 2d | 1,229 | $75 | $92K | Form 4 ↗ | ||
| BSX | Option / conversion M | February 16, 2026 | February 18, 2026 | 2d | 2,546 | — | — | Form 4 ↗ | ||
| BSX | Sell F | February 14, 2026 | February 18, 2026 | 4d | 1,535 | $75 | $115K | Form 4 ↗ | ||
| BSX | Option / conversion M | February 14, 2026 | February 18, 2026 | 4d | 3,173 | — | — | Form 4 ↗ | ||
| BSX | Sell F | February 13, 2026 | February 18, 2026 | 5d | 25,150 | $75 | $1.9M | late | Form 4 ↗ | |
| BSX | Option / conversion M | February 13, 2026 | February 18, 2026 | 5d | 2,237 | — | — | late | Form 4 ↗ | |
| BSX | Other A | February 13, 2026 | February 18, 2026 | 5d | 25,380 | — | — | late | Form 4 ↗ | |
| BSX | Other A | February 13, 2026 | February 18, 2026 | 5d | 25,380 | — | — | late | Form 4 ↗ | |
| BSX | Other A | February 12, 2026 | February 17, 2026 | 5d | 35,817 | — | — | latederivative | Form 4 ↗ | |
| BSX | Other A | February 12, 2026 | February 17, 2026 | 5d | 15,178 | — | — | latederivative | Form 4 ↗ | |
| BSX | Option / conversion M | February 12, 2026 | February 17, 2026 | 5d | 2,692 | — | — | latederivative | Form 4 ↗ | |
| BSX | Sell F | February 12, 2026 | February 17, 2026 | 5d | 1,302 | $74 | $97K | late | Form 4 ↗ | |
| BSX | Option / conversion M | February 12, 2026 | February 17, 2026 | 5d | 2,692 | — | — | late | Form 4 ↗ | |
| BSX | Option / conversion M | December 1, 2025 | December 2, 2025 | 1d | 3,177 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| BSX | Option / conversion M | December 1, 2025 | December 2, 2025 | 1d | 6,175 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| BSX | Option / conversion M | December 1, 2025 | December 2, 2025 | 1d | 1,009 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| BSX | Option / conversion M | December 1, 2025 | December 2, 2025 | 1d | 6,952 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| BSX | Sell S | December 1, 2025 | December 2, 2025 | 1d | 17,313 | $102 | $1.8M | 10b5-1 plan | Form 4 ↗ | |
| BSX | Option / conversion M | December 1, 2025 | December 2, 2025 | 1d | 1,009 | $17 | $17K | 10b5-1 plan | Form 4 ↗ | |
| BSX | Option / conversion M | December 1, 2025 | December 2, 2025 | 1d | 3,177 | $23 | $72K | 10b5-1 plan | Form 4 ↗ | |
| BSX | Option / conversion M | December 1, 2025 | December 2, 2025 | 1d | 6,175 | $25 | $152K | 10b5-1 plan | Form 4 ↗ | |
| BSX | Option / conversion M | December 1, 2025 | December 2, 2025 | 1d | 6,952 | $27 | $188K | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 4, 2026 | Form 4 | 0001225208-26-004896 | 3 | published | EDGAR ↗ |
| February 27, 2026 | Form 4 | 0001225208-26-002794 | 1 | published | EDGAR ↗ |
| February 18, 2026 | Form 4 | 0001225208-26-002133 | 11 | published | EDGAR ↗ |
| February 17, 2026 | Form 4 | 0001225208-26-002014 | 5 | published | EDGAR ↗ |
| December 2, 2025 | Form 4 | 0001225208-25-009597 | 9 | published | EDGAR ↗ |
Other insiders at BOSTON SCIENTIFIC CORP
- Mahoney Michael F Chairman, President & CEO 30 rows
- Fitzgerald Joseph Michael EVP & Group Pres, Cardiology 28 rows
- O'Connor Padraig Andrew EVP, Global Operations 20 rows
- Monson Jonathan EVP and CFO 18 rows
- Woodworth Emily SVP, Global Controller and CAO 18 rows
- Brown Vance R EVP, GC and Corp. Secretary 16 rows
- O'Sullivan Miriam SVP, Chief HR Officer 15 rows
- Zane Ellen M Director 14 rows
- Smith Cathy R Director 11 rows
- Habiger David C Director 6 rows
Everyone on file, with contracts and lobbying under the company's name: BOSTON SCIENTIFIC CORP.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 5 | 29 | December 2, 2025 | May 4, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.